NetworkNewsBreaks – Syros Pharmaceuticals, Inc.’s (NASDAQ: SYRS) Advancements in CDK Inhibition Featured in ROTH Equity Research Report
Syros Pharmaceuticals (NASDAQ: SYRS) was featured in a recent Equity Research Report published by ROTH Capital Partners, LLC. The report reads, “Yesterday, Syros announced new preclinical data showcasing the differentiating therapeutic effects of its CDK7 vs CDK12/13 inhibitors. More broadly, the company highlighted its platform's potential to identify genes and transcriptional regulators of cancer, which should enable the identification of new drug targets to further expand its pipeline of small-molecule inhibitors. With this update, coupled with the entry of Syros' next-gen CDK7 inhibitor (SY-5609) into the clinic, we invite you to join our call with a renowned expert on gene…







